|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | C07D 487/04 | |
| A61K 31/519 | |||
| A61P 35/00 | |||
| A61P 37/06 |
| (11) | Patento numeris | 2861599 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 13731218.7 |
| Europos patento paraiškos padavimo data | 2013-06-11 | |
| (97) | Europos patento paraiškos paskelbimo data | 2015-04-22 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2019-12-18 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2013/045266 |
| Data | 2013-06-11 |
| (87) | Numeris | WO 2013/191965 |
| Data | 2013-12-27 |
| (30) | Numeris | Data | Šalis |
| 201261661203 P | 2012-06-18 | US |
| (72) |
GOLDSTEIN, David Michael, US
BERNER, Bret, US
|
| (73) |
Principia Biopharma Inc.,
220 E. Grand Ave., S. San Francisco, CA 94080,
US
|
| (54) | REVERSIBLE COVALENT PYRROLO- OR PYRAZOLOPYRIMIDINES USEFUL FOR THE TREATMENT OF CANCER AND AUTOIMMUNE DISEASES |
| REVERSIBLE COVALENT PYRROLO- OR PYRAZOLOPYRIMIDINES USEFUL FOR THE TREATMENT OF CANCER AND AUTOIMMUNE DISEASES |